Mike Wang - Carl Zeiss Head Shanghai

All Insiders . USA . 
Stock . Carl Zeiss Meditec . Stakeholders . Insider . Mike Wang
CZMWF Stock  USD 61.22  0.00  0.00%   

Insider

Mike Wang is Head Shanghai of Carl Zeiss Meditec
Phone49 3641 220 115
Webhttps://www.zeiss.de/meditec-ag/home.html

Carl Zeiss Management Efficiency

The company has return on total asset (ROA) of 0.0955 % which means that it generated a profit of $0.0955 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1596 %, meaning that it generated $0.1596 on every $100 dollars invested by stockholders. Carl Zeiss' management efficiency ratios could be used to measure how well Carl Zeiss manages its routine affairs as well as how well it operates its assets and liabilities.
Carl Zeiss Meditec has accumulated 120.05 M in total debt with debt to equity ratio (D/E) of 0.07, which may suggest the company is not taking enough advantage from borrowing. Carl Zeiss Meditec has a current ratio of 3.28, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Carl Zeiss until it has trouble settling it off, either with new capital or with free cash flow. So, Carl Zeiss' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Carl Zeiss Meditec sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Carl to invest in growth at high rates of return. When we think about Carl Zeiss' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Holger HadererStraumann Holding AG
54
Andrew ChangCarl Zeiss Meditec
N/A
Augustine JDHOYA Corporation
55
Aurelio SahagunStraumann Holding AG
50
KokKien LohStraumann Holding AG
56
Martin WiechmannCarl Zeiss Meditec
N/A
Marco CatalaniEssilorLuxottica Socit anonyme
N/A
Ariel BauerEssilorLuxottica Socit anonyme
N/A
Euan ThomsonCarl Zeiss Meditec
60
Rahma SamowStraumann Holding AG
44
Camila FinziStraumann Holding AG
51
Dorthe RonnauColoplast AS
57
Tomoko NakagawaHOYA Corporation
N/A
Markus WeberCarl Zeiss Meditec
N/A
Steven MDCarl Zeiss Meditec
N/A
Giorgio IannellaEssilorLuxottica Socit anonyme
N/A
Laurie FergusonCarl Zeiss Meditec
N/A
Taishi ArashidaHOYA Corporation
N/A
Alastair RobertsonStraumann Holding AG
63
Ellen BjurgertColoplast AS
N/A
Dennis KaysenColoplast AS
N/A
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 3531 people. Carl Zeiss Meditec [CZMWF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Return On Equity0.16
Return On Asset0.0955

Carl Zeiss Meditec Leadership Team

Elected by the shareholders, the Carl Zeiss' board of directors comprises two types of representatives: Carl Zeiss inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Carl. The board's role is to monitor Carl Zeiss' management team and ensure that shareholders' interests are well served. Carl Zeiss' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Carl Zeiss' outside directors are responsible for providing unbiased perspectives on the board's policies.
Sebastian Frericks, Director Investor Relations
Laurie Ferguson, Head Devices
Markus Weber, CEO Pres
Martin Wiechmann, Head Unit
Andrew Chang, I Meditec
Euan Thomson, Pres Unit
Steven MD, Chief Devices
Justus Wehmer, CFO, Member of the Management Board
Mike Wang, Head Shanghai

Carl Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Carl Zeiss a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.16
Return On Asset0.0955
Profit Margin0.15 %
Operating Margin0.21 %
Current Valuation12.07 B
Shares Outstanding89.44 M
Shares Owned By Insiders59.10 %
Shares Owned By Institutions22.23 %
Price To Earning75.63 X
Price To Book6.17 X

Currently Active Assets on Macroaxis

TITANTitan Company Limited
UUnity Software
PAYCPaycom Soft
HBIHanesbrands
STLDSteel Dynamics

Other Information on Investing in Carl Pink Sheet

Carl Zeiss financial ratios help investors to determine whether Carl Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Carl with respect to the benefits of owning Carl Zeiss security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY